Navigation Links
Type 2 diabetes study to examine role amylin plays in disease

WASHINGTONA George Washington University researcher will receive $1.3 million over the next five years from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for research that will help better understand how type 2 diabetes develops, possibly informing the development of novel treatments to reverse the disease.

The research is particularly important given 150 million people worldwide suffer from type 2 diabetes--a number expected to double over the next 20 years.

Aleksandar Jeremic, an associate professor of biology in the Columbian College of Arts and Sciences, along with a team of GW undergraduate students, graduate students and postdoctoral fellows, will study the role amylin--a hormone that, like insulin, is secreted by the pancreas to regulate blood sugar levels--plays in the development of type 2 diabetes. When amylin aggregates in the pancreas and forms protein deposits, it can kill insulin-producing beta-cells, leading to type 2 diabetes.

Using high-resolution imaging approaches such as confocal and atomic force microscopy, which can produce a scan at the nanometer resolution, the GW team will investigate the molecular and biochemical events that lead to the aggregation of human amylin.

"We know of many factors, such as poor diet and inactivity, that contribute to type 2 diabetes," Dr. Jeremic said. "What is less clear, but no less important, is the role amylin plays in the development of the disease. Our research may also provide a better understanding of the biological role of this important signaling molecule in the human body."

Ultimately, the information could contribute to new treatments for type 2 diabetes, for example, by preventing the aggregation of amylin or making cells less susceptible to the toxic effects of the buildup.

The project, "Molecular Mechanisms of Amylin Trafficking and Toxicity in Human Pancreatic Islets," NIH grant R01DK091845, will be funded by the NIDDK, part of the National Institutes of Health, for the next five years.


Contact: Kurtis Hiatt
George Washington University

Related biology news :

1. ITN type 1 diabetes study identifies subset of patients with strong response to therapy
2. Obesity and mortality association differs between individuals with and without diabetes
3. Healthrageous, United BioSource And Boehringer Ingelheim Launch SMART Digital Diabetes Study
4. Diet additions may help youth with type 1 diabetes keep producing own insulin
5. DNA abnormalities may contribute to cancer risk in people with type 2 diabetes
6. Infants food linked to higher, lower Type 1 diabetes risk
7. Type 2 diabetes patients transplanted with own bone marrow stem cells reduces insulin use
8. National Institutes of Health to fund research probing proteins linked to cancer, diabetes
9. Mercy Lab Offers Faster On-demand Diabetes Testing, Cellular Studies
10. New data on islet autoantibodies in young children defines early type 1 diabetes development
11. Breakthrough research of essential molecule reveals important targets in diabetes and obesity
Post Your Comments:
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
Breaking Biology Technology: